Company Overview - CG Oncology, Inc. is a clinical-stage biotechnology company focused on innovative therapies for bladder cancer, particularly bladder-sparing treatments [6] - The company is developing cretostimogene, a therapeutic candidate targeting high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy [8] - CG Oncology's business model is centered on developing novel oncology therapeutics through clinical development, targeting healthcare providers treating bladder cancer patients [8] Financial Metrics - As of February 18, 2026, CG Oncology's stock price was $55.21, reflecting a 101.7% increase over the past year [7] - The company's market capitalization stands at $4.45 billion, with a trailing twelve months (TTM) revenue of $2.17 million and a net income of -$151.48 million [4] Recent Developments - Braidwell sold 1,412,746 shares of CG Oncology, reducing its position by approximately $58.46 million, which resulted in a decline of $54.59 million in the fund's quarter-end value in CG Oncology [2][5] - Following the sale, Braidwell's stake in CG Oncology now represents 2.48% of its reportable U.S. equity assets [7] Clinical Progress - CG Oncology has accelerated its Phase 3 timeline for the PIVOT-006 trial in intermediate-risk NMIBC, expecting topline data in the first half of 2026, nearly a year ahead of schedule [9] - The trial has enrolled over 360 patients across more than 90 sites, indicating strong execution and potential for significant stock performance [9] Market Opportunity - CG Oncology is targeting a population of over 50,000 intermediate-risk patients in the U.S. with no FDA-approved adjuvant options currently available [11] - Successful Phase 3 data could lead to substantial commercial opportunities, while failure may result in increased volatility [11]